問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Urology

Division of Hematology & Oncology

更新時間：2023-09-19

蕭博任Hsiao, Po-Jen
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

37Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蕭博任

List

47Cases

2021-12-20 - 2031-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-04-30 - 2024-12-31

Phase III

Completed
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

  • Condition/Disease

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • Test Drug

    Keytruda® injection /Lynparza® Film-coated Tablets

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2022-01-01 - 2024-07-31

Phase III

Completed
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Unresectable Urothelial Cancer

  • Test Drug

    Sacituzumab Govitecan

Participate Sites
11Sites

Recruiting11Sites

2020-07-22 - 2025-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-05-02 - 2028-12-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-08-01 - 2029-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-03-25 - 2026-07-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2016-07-28 - 2020-11-01

Phase III

A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Avelumab (MSB0010718C)

Participate Sites
6Sites

Terminated6Sites

2017-11-01 - 2022-12-31

Phase I/II

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After, or are Refractory to Standard Therapy.

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cell Carcinoma

  • Test Drug

    Vofatamab (B-701)

Participate Sites
9Sites

Terminated8Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB